Mereo BioPharma Group (MREO) Competitors $4.28 +0.07 (+1.66%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MREO vs. SRRK, ACAD, TWST, LBPH, ME, KROS, VERA, SWTX, VCEL, and AKROShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), Longboard Pharmaceuticals (LBPH), 23andMe (ME), Keros Therapeutics (KROS), Vera Therapeutics (VERA), SpringWorks Therapeutics (SWTX), Vericel (VCEL), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Scholar Rock ACADIA Pharmaceuticals Twist Bioscience Longboard Pharmaceuticals 23andMe Keros Therapeutics Vera Therapeutics SpringWorks Therapeutics Vericel Akero Therapeutics Scholar Rock (NASDAQ:SRRK) and Mereo BioPharma Group (NASDAQ:MREO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation. Which has higher earnings & valuation, SRRK or MREO? Mereo BioPharma Group has lower revenue, but higher earnings than Scholar Rock. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M68.53-$165.79M-$2.22-12.80Mereo BioPharma Group$1M600.30-$29.47MN/AN/A Does the MarketBeat Community prefer SRRK or MREO? Scholar Rock received 117 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 76.79% of users gave Mereo BioPharma Group an outperform vote while only 65.04% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformScholar RockOutperform Votes16065.04% Underperform Votes8634.96% Mereo BioPharma GroupOutperform Votes4376.79% Underperform Votes1323.21% Do analysts prefer SRRK or MREO? Scholar Rock currently has a consensus price target of $33.29, suggesting a potential upside of 17.12%. Mereo BioPharma Group has a consensus price target of $7.50, suggesting a potential upside of 75.23%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do institutionals and insiders believe in SRRK or MREO? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 19.2% of Scholar Rock shares are held by company insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to SRRK or MREO? In the previous week, Scholar Rock had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 4 mentions for Scholar Rock and 0 mentions for Mereo BioPharma Group. Scholar Rock's average media sentiment score of 0.47 beat Mereo BioPharma Group's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media. Company Overall Sentiment Scholar Rock Neutral Mereo BioPharma Group Neutral Is SRRK or MREO more profitable? Mereo BioPharma Group's return on equity of 0.00% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -114.96% -77.22% Mereo BioPharma Group N/A N/A N/A Which has more risk & volatility, SRRK or MREO? Scholar Rock has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. SummaryMereo BioPharma Group beats Scholar Rock on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$600.30M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93115.5615.18Price / Sales600.30381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book11.895.324.665.02Net Income-$29.47M$153.56M$119.06M$225.46M7 Day Performance0.47%0.11%0.80%0.37%1 Month Performance-0.23%15.22%5.65%3.57%1 Year Performance106.76%41.14%36.76%29.44% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group1.7813 of 5 stars$4.28+1.7%$7.50+75.2%+114.0%$600.30M$1M0.0040Positive NewsSRRKScholar Rock4.6384 of 5 stars$29.91+3.1%$33.29+11.3%+131.1%$2.39B$33.19M-13.47140Upcoming EarningsACADACADIA Pharmaceuticals4.518 of 5 stars$14.34-1.0%$25.56+78.3%-35.4%$2.37B$890.53M79.67510Upcoming EarningsTWSTTwist Bioscience3.5896 of 5 stars$40.60+0.9%$51.22+26.2%+166.1%$2.36B$295.21M-10.63990LBPHLongboard Pharmaceuticals1.5861 of 5 stars$59.60+0.1%$59.56-0.1%+1,013.6%$2.32BN/A-27.7220Upcoming EarningsME23andMe1.9247 of 5 stars$4.67-3.7%$9.40+101.3%-71.6%$2.29B$199.19M-0.18770Gap DownKROSKeros Therapeutics3.4512 of 5 stars$60.76+2.0%$89.11+46.7%+109.7%$2.28B$150,000.00-11.84100Upcoming EarningsShort Interest ↓Positive NewsVERAVera Therapeutics2.3586 of 5 stars$41.09+3.3%$52.67+28.2%+300.9%$2.25BN/A-18.5940Insider SellingSWTXSpringWorks Therapeutics1.2098 of 5 stars$29.31+0.7%$68.50+133.7%+28.1%$2.17B$86.19M-6.62305VCELVericel2.5172 of 5 stars$43.75+2.1%$57.71+31.9%+25.7%$2.13B$214.52M-4,375,000.00300Upcoming EarningsNews CoverageAKROAkero Therapeutics3.9016 of 5 stars$29.33+2.0%$43.20+47.3%+144.7%$2.03BN/A-8.6030Insider SellingNews CoverageGap Up Related Companies and Tools Related Companies SRRK Competitors ACAD Competitors TWST Competitors LBPH Competitors ME Competitors KROS Competitors VERA Competitors SWTX Competitors VCEL Competitors AKRO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MREO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
